Bb5a31f81ClaimMeta's stock price declined by nearly 2% following the announcement of its $95 billion equity offering planAgreeDisagree
Bb5a31f81ClaimMeta announced a plan to raise up to $95 billion through successive stock sales to finance artificial intelligence infrastructureAgreeDisagree
Bb5a31f81ClaimAnthropic's losses exceeding $80 billion were driven primarily by an accounting adjustment related to financing agreementsAgreeDisagree
Bb5a31f81ClaimAnthropic recorded net losses exceeding $80 billion for the six months ending June 30thAgreeDisagree
Bb5a31f81ClaimAnthropic generated approximately $16 billion in revenue during the six-month period ending June 30thAgreeDisagree
Bb5a31f81ClaimAnthropic seeks to sell approximately $100 billion worth of shares in its initial public offeringAgreeDisagree
Bb5a31f81ClaimNvidia, AMD, and Broadcom expressed interest in purchasing portions of Meta's newly issued equityAgreeDisagree
Bb5a31f81ClaimAnthropic scheduled its initial public offering investor roadshow to begin roughly two weeks after filing its S-1AgreeDisagree
Bb5a31f81ClaimAnthropic filed an S-1 registration statement with regulators to launch an initial public offeringAgreeDisagree
Bb5a31f81ClaimRisk factors constitute approximately one-quarter of Anthropic's 400-page S-1 filingAgreeDisagree
Bb5a31f81ClaimMeta's $95 billion financing plan comprises roughly $35 billion in public offerings alongside a newly created class of non-voting stockAgreeDisagree
Bb5a31f81ClaimClaude Sonnet 5.5 achieved strong performance on Leash Bio's chemical exploration benchmarkAgreeDisagree
Bb5a31f81ClaimMoonshot explicitly instructed social media influencers promoting Kimi K3.1 to omit paid partnership disclosure labels from their postsAgreeDisagree
Bb5a31f81ClaimClaude Sonnet 5 exhibited high operational costs and low performance on Leash Bio's chemical exploration benchmarkAgreeDisagree
Bb5a31f81ClaimOpenAI stated in a public security disclosure that additional software vulnerabilities would be revealedAgreeDisagree
Bb5a31f81ClaimSolve 6.1 demonstrated high performance on Leash Bio's chemical exploration benchmarkAgreeDisagree
Bb5a31f81ClaimRamp data showed Claude Opus 5.5 captured 35.1% of token share and 34.4% of business spend across tracked modelsAgreeDisagree
Bb5a31f81ClaimArtificial Analysis determined that Kimi K3.1 consumes 14% more tokens per task than Kimi K3AgreeDisagree
Bb5a31f81ClaimMoonshot priced Kimi K3.1 at the same per-token rate as Sonnet 5.5 and GPT6 SOLAgreeDisagree